Please contact Matt Crocker at crockerm@ohsu.edu or 503-418-9389 with questions.

http://www.ohsu.edu/research/rda/so/knight.php
**HER2 POSITIVE**

- **Pre-Op Therapy**
  - IRB# 6256
  - ISPY2
  - Investigation of Serial Studies to Predict Your Therapeutic Response with Imaging and Molecular Analysis 2

- **Surgical Therapy**
  - No Trial Currently Available

- **Adjuvant Therapy**
  - No Trial Currently Available

- **1st Line MBC Therapy**
  - IRB # 19078
  - S1501: Prospective Evaluation of Carvediolol in Prevention of Cardiac Toxicity in Patients with Metastatic HER2+ BC, Phase III

- **2nd or 3rd Line MBC Therapy**
  - IRB#19830
  - T-DM1 and Palbociclib in Metastatic HER2+ BC

- **Heavily Pre-Treated Therapy**
  - IRB #20112
  - T-DM1 and Tucatinib or Placebo in Metastatic HER2+ BC

**CROSS-DISEASE TRIALS:**

- IRB 19992
  - EAV131 (MATCH)

- IRB 18084
  - S1609 DART

**Key**

- Open for Enrollment
- In Development
- Enrollment on Hold

http://www.ohsu.edu/research/rda/so/knight.php